Ticker: KALV

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) - quick read What's happening inside the company - FDA approved EKTERLY® (sebetralstat) on July 3, 2025; this is KalVista's first commercial product and the first oral on‑demand therapy for hereditary angioedema (HAE). - Commercial launch in the U.S. ...

Company Overview KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is a pre-commercial stage pharmaceutical company focused on developing treatments for hereditary angioedema (HAE). The firm is advancing its lead candidate, sebetralstat, and has several regulatory applications pending in the U.S., Eu...